Follow the people · Insider
Seshu Tyagarajan
Seshu Tyagarajan files insider transactions with the SEC as a chief technology officer of Candel Therapeutics (CADL). We hold 2 disclosed purchases and sales filed since 15 April 2022, 2 of them in the last 90 days.
- Files forCADL
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure19 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 14 April 2022 — 17 August 2026Chief Technology Officer · Candel Therapeutics (CADL)23 Form 4 lines · source: SEC Form 4
Everything they disclosed
23 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 7,000 shares of Candel TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 7,000 shares of Candel TherapeuticsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- was granted 154,000 shares of Candel Therapeutics (a derivative holding)SEC Form 428 January 2026Stock Option (Right to Buy) · traded 26 January 2026 · filed 28 January 2026
- was granted 154,000 shares of Candel Therapeutics (a derivative holding)SEC Form 428 January 2026Stock Option (Right to Buy) · traded 26 January 2026 · filed 28 January 2026
- was granted 5,353 shares of Candel TherapeuticsSEC Form 426 June 2025Common Stock · traded 25 June 2025 · filed 26 June 2025
- exercised options over 20,000 shares of Candel Therapeutics (a derivative holding)SEC Form 420 March 2025Stock Option (Right to Buy) · traded 17 March 2025 · filed 20 March 2025
- exercised options over 20,000 shares of Candel TherapeuticsSEC Form 420 March 2025Common Stock · traded 17 March 2025 · filed 20 March 2025
- ▼ sold on the open market 31,278 shares of Candel TherapeuticsSEC Form 420 March 2025Common Stock · traded 17 March 2025 · filed 20 March 2025
- exercised options over 20,000 shares of Candel Therapeutics (a derivative holding)SEC Form 419 March 2025Stock Option (Right to Buy) · traded 17 March 2025 · filed 19 March 2025
- ▼ sold on the open market 31,278 shares of Candel TherapeuticsSEC Form 419 March 2025Common Stock · traded 17 March 2025 · filed 19 March 2025
- was granted 65,000 shares of Candel Therapeutics (a derivative holding)SEC Form 414 February 2025Stock Option (Right to Buy) · traded 12 February 2025 · filed 14 February 2025
- ▼ sold on the open market 14,322 shares of Candel TherapeuticsSEC Form 417 January 2025Common Stock · traded 15 January 2025 · filed 17 January 2025
- ▼ sold on the open market 14,545 shares of Candel TherapeuticsSEC Form 410 January 2025Common Stock · traded 8 January 2025 · filed 10 January 2025
- ▼ sold on the open market 20,392 shares of Candel TherapeuticsSEC Form 43 December 2024Common Stock · traded 29 November 2024 · filed 3 December 2024
- ▼ sold on the open market 14,851 shares of Candel TherapeuticsSEC Form 419 July 2024Common Stock · traded 17 July 2024 · filed 19 July 2024
- ▼ sold on the open market 13,330 shares of Candel TherapeuticsSEC Form 415 July 2024Common Stock · traded 11 July 2024 · filed 15 July 2024
- had shares withheld for tax on 17,328 shares of Candel TherapeuticsSEC Form 430 November 2023Common Stock · traded 28 November 2023 · filed 30 November 2023
- was granted 104,516 shares of Candel TherapeuticsSEC Form 428 November 2023Common Stock · traded 26 November 2023 · filed 28 November 2023
- was granted 90,000 shares of Candel Therapeutics (a derivative holding)SEC Form 42 May 2023Stock Option (Right to Buy) · traded 28 April 2023 · filed 2 May 2023
- ▲ bought on the open market 3,000 shares of Candel TherapeuticsSEC Form 412 December 2022Common Stock · traded 8 December 2022 · filed 12 December 2022
- ▲ bought on the open market 10,358 shares of Candel TherapeuticsSEC Form 412 December 2022Common Stock · traded 9 December 2022 · filed 12 December 2022
- was granted 73,684 shares of Candel TherapeuticsSEC Form 430 November 2022Common Stock · traded 28 November 2022 · filed 30 November 2022
- was granted 120,000 shares of Candel Therapeutics (a derivative holding)SEC Form 415 April 2022Stock Option (Right to Buy) · traded 14 April 2022 · filed 15 April 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.